DCIS in the RRt group showed a more aggressive profile (grade 3, large size, and HER2 overexpression) and higher LR risk without RT, with a 10-year rate of total LRs of 42.1% and invasive LRs of 18.5%. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.